A Little Recognition, Please
Executive Summary
Wall Street wasn't thrilled this August when T-Cell Sciences Inc. announced that it would acquire Virus Research Institute Inc. and its development-stage vaccines. But CEO Una Ryan, PhD, says the newly-merged company, Avant Immunotherapeutics Inc., is badly undervalued.